Locations:
Search IconSearch
February 22, 2021/Cancer/Radiation Oncology

IMRT for Diffuse Cutaneous Breast Cancer Metastases

Minimizing patient discomfort, improving quality of life

650×450-Breast-Cancer-Skin-Reoccurances

Thanks to advances in screening and treatments, patients with breast cancer are living longer. As a result, diffuse cutaneous metastases are becoming more common, and these skin lesions can severely impact patient quality of life. Cleveland Clinic Cancer Center’s Department of Radiation Oncology has developed techniques that minimize patient discomfort and improve quality of life using streamlined intensity-modulated radiation therapy (IMRT).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“There’s a common myth that once a patient has been treated with radiation for breast cancer, they cannot be treated again, or that the area of skin metastases is too large to treat,” says Chirag Shah, MD, Director of Breast Radiation Oncology at Cleveland Clinic Cancer Center. “We absolutely can use radiation on large, diffuse skin metastases while sparing the heart and lung, which is really important because these cases are not commonly treated with surgical interventions.”

Conventional techniques, such as 3-dimension conformal radiation therapy and electron fields, are difficult to set up and cannot spare normal tissues as well in the re-irradiation setting. With IMRT, patients can receive high doses of radiation that avoid normal tissues and are effective in re-irradiation. Some centers use this approach for diffuse cutaneous metastases, but no published guidelines or preferred methodologies exist.

IMRT techniques

A recent report published in The Breast Journal offers a methodology that improved quality of life for several patients and is preferred by Cleveland Clinic clinicians for patients presenting with such clinical indications. The report discusses five patients who initially had locally advanced, nonmetastatic breast cancer and a median time to metastatic recurrence of 17 months. Four of five patients had been treated with postmastectomy radiation therapy (PMRT).

Pictures of patients treated with postmastectomy radiation therapy (PMRT).

Clinical presentation. (A) Right axilla (B) Chest wall (C) Posterior chest wall (D) Posterior chest wall one month after completion of 30 Gy in 10 fractions with near complete response. Figure and caption republished with permission from Wiley.

Advertisement

“Our preferred technique involves mapping areas of disease and then wiring 2 to 3 centimeters beyond that while placing bolus to enhance skin dose. Then we utilize the treatment planning system to turn the wires into a volume to be treated. The patients are lying down, and this takes about an hour,” says Dr. Shah, senior author of the paper.

A dosimetrist working with a computer algorithm turns the map into preliminary radiation targets, which clinicians review and adjust to ensure accuracy. The dosimetrist in conjunction with the algorithm then develops an IMRT plan that spares normal tissue. Patients with metastatic disease and previous RT commonly receive a range of doses from 30 to 66 Gy/10 to 33 fractions.

Of the five patients in the report, four patients experienced a complete or near complete response at three months. Two had received concurrent hyperthermia during IMRT. All experienced grade 3 dermatitis.

“These patients can be very ill, and of the five we treated, three have since passed away,” says Dr. Shah. “But our efforts to alleviate their pain and improve their quality of life by reducing their burden of cutaneous metastases are an important part of what we do here. Patients with severe cancer recurrences can have improved quality of life with the proper planning and techniques.”

Advertisement

Related Articles

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Dr. Gerds
December 8, 2025/Cancer/News & Insight
AI Screening Platform Accelerates Trial Recruitment in Polycythemia Vera

AI-driven tools can streamline enrollment and improve efficiency across clinical trials.

PET scan after CAR T-cell therapy
December 5, 2025/Cancer/Blood Cancers
Case Study: Overcoming Communication Barriers to Enroll Patient in CAR T-Cell Therapy Clinical Trial

Patient achieves complete remission from aggressive marginal zone lymphoma with liso-cel

Dr. Roesch
November 28, 2025/Cancer
Management of Pregnancy-Associated Breast Cancer (Podcast)

Supporting patients during pregnancy and beyond

Dr. Abraham
November 26, 2025/Cancer/News & Insight
Artificial Intelligence in Oncology (Podcast)

Real-world applications in clinical documentation and trial matching

Ad